Rachel Sanborn, M.D.
Dr Rachel E. Sanborn
Dr. Sanborn is a Full Member of the Earle A. Chiles Research Institute at the Providence Cancer Institute in Portland, Oregon. She is the Medical Director of the Thoracic Oncology Program and Medical Director of the Phase I Clinical Trials Program. She leads a robust portfolio of clinical trials that include cutting-edge research in targeted therapies, novel treatment approaches, and early-stage and combination immunotherapeutics for lung cancer, other thoracic malignancies, and other cancers. She is a member of the Providence Institutional Review Board, the American Lung Association Medical Advisory Workgroup, as well as the Southwest Oncology Group Lung Cancer Working Group and Community Engagement Committee. She has served as co-chair of the Hoosier Cancer Research Network Thoracic Clinical Trials Working Group and is a member of the American Society of Clinical Oncology as well as the International Association for the Study of Lung Cancer.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AstraZenecaTopic:Advisory board, steering committee, educational moderator, funding for investigator-sponsored trialDate added:09/26/2022Date updated:04/29/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:EMD SeronoTopic:Advisory boardDate added:09/26/2022Date updated:04/29/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Daiichi SankyoTopic:Advisory boardDate added:09/26/2022Date updated:04/29/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Lilly OncologyTopic:Advisory boardDate added:09/26/2022Date updated:04/29/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Janssen OncologyTopic:Advisory board, steering committeeDate added:09/26/2022Date updated:04/29/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:MacrogenicsTopic:Advisory boardDate added:09/26/2022Date updated:04/29/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Sanofi AventisTopic:Advisory boardDate added:09/26/2022Date updated:04/29/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:RegeneronTopic:Advisory boardDate added:09/26/2022Date updated:04/29/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Mirati TherapeuticsTopic:Advisory boardDate added:09/26/2022Date updated:04/29/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GlaxoSmithKlineTopic:Advisory boardDate added:09/26/2022Date updated:04/29/2024